65,437 trials
Suicidal Ideation
Primary: Feasibility of the Intervention: Number of Participants Who Completed 5 or More Remotely Supervised Transcranial Direct Current Stimulation (RS-tDCS) Sessions — 4; 3…
Heart Failure; With Decompensation
Primary: Number of Participants With HF-related Healthcare Resource Utilization (HCRU) — 64; 59 Participants
Dysphagia, Oral Phase · Stroke, Ischemic
Primary: Adherence — 79 percentage of adherence
Dry Eye
Primary: Mean Corneal Thickness — 570.54; 560.73 microns — p=0.25
Prostate Cancer
Primary: Assessing Percentage of Participants Who Reported Adverse Events Following Treatment by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 — 4.1; 4.3; 4.1; 10…
Amyotrophic Lateral Sclerosis
Primary: Safety of Intramuscular Injections of Engensis in Participants With Amyotrophic Lateral Sclerosis Compared to Placebo — 4; 3; 3; 1 Participants
Type 2 Diabetes Mellitus · Heart Failure
Primary: Fractional Excretion of Lithium (FELi) — 0.3; -2.3; 0.8; -4.9 percentage of filtered lithium excreted — p=0.36
Severe Hypoglycemia
Primary: Self-reported Severe Hypoglycemia — 99; 99; 19; 13 Participants — p=0.27
Opioid-use Disorder
Primary: Urine Drug Screening Test Results — 92.3; 92.0; 1.9; 2.0 percentage of participants positive
Fecal Incontinence · Bowel Incontinence
Primary: Treatment Response Defined as a 75% or Greater Change in Number of Average Weekly FI Episodes at Month 3 Follow-Up Compared to Baseline — 29; 28 Participants
Healthy
Primary: Area Under the Concentration-Time Curve From Time Zero to The Time of The Last Quantifiable Concentration (AUClast) of Sisunatovir PIC Versus (vs) WGT in a Fasted State…
Respiratory Syncytial Virus Infections
Primary: Infants: Percentages of Participants With Medically Significant RSV LRTI With Either Hypoxemia (SpO2 <95% at Sea Level or <92% at Altitudes >1800 Meters) or Tachypnea…
Masseter Muscle Prominence
Primary: Achievement of ≥ 2-Grade Improvement From Baseline on the Masseter Muscle Prominence Scale (MMPS) at Day 90 — 2.2; 51.2 percentage of participants — p=<0.0001
Antibody-mediated Rejection · Kidney Transplant; Complications · Transplant Glomerulopathy
Primary: Number of Participants With Donor Specific Antibody (DSA) Elimination or Reduction Based on Luminex HLA Testing — 7 Participants
Critical Illness · Delirium · Cognitive Impairment
Primary: Number of Days Alive Without Delirium or Coma — 7.00; 8.50 days